Roth Capital optimistic on Chelsea Therapeutics The important takeaway from Chelsea Therapeutics' (CHTP -2.9%) Q2 report is that the re-filing for Northera remains on track for this month, Roth Capital says, maintaining a Buy rating and a $4 price target. Late last month the FDA identified certain "technical deficiencies" in the NDA for Northera. There are "no surprises in the 10-Q," and "the risk/reward" is favorable for "risk-tolerant investors," Roth adds.